Bausch + Lomb chief executive Brent Saunders said an increasing demand for age and diabetes-related eye disease treatments will allow Bausch + Lomb's pharmaceuticals division to become the company's largest, according to a Wall Street Journal report.
Mr. Saunders believes the eye health market will grow 20 percent over the next two years. Currently the company's portfolio is 40 percent pharmaceutical, 40 percent vision and 20 percent surgical. Next year, the company expects that to change to 42 percent for pharmaceutical, 38 percent for vision care and 20 percent for surgical.
Related Articles on Ophthalmology:
Eyelid Surgery Provides Significant Improvement in Vision
VICTUS Femtosecond Laser Platform Gets CE Mark Approval
TearLab Gets FDA Approval for Wider Use of Eye Test
Mr. Saunders believes the eye health market will grow 20 percent over the next two years. Currently the company's portfolio is 40 percent pharmaceutical, 40 percent vision and 20 percent surgical. Next year, the company expects that to change to 42 percent for pharmaceutical, 38 percent for vision care and 20 percent for surgical.
Related Articles on Ophthalmology:
Eyelid Surgery Provides Significant Improvement in Vision
VICTUS Femtosecond Laser Platform Gets CE Mark Approval
TearLab Gets FDA Approval for Wider Use of Eye Test